Active	Status	Sponsor type	Region	Phase	Filter
3 Active 4 Inactive 7 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other Show only owner-sponsored trials	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

3 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Lymphir (denileukin diftitox-cxdl) / Eisai, Citius Oncology
NCT04855253: Study of E7777 Prior to Kymriah for R/R DLBCL	Recruiting	1/2	30	US	E7777	Masonic Cancer Center, University of Minnesota	DLBCL, Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma, DLBCL Arising From Follicular Lymphoma	12/25	12/25
HCC 21-166, NCT05200559: T-regulatory Cell Depletion with E7777 Combined with Pembrolizumab in Recurrent or Metastatic Solid Tumors	Recruiting	1/2	70	US	Pembrolizumab, Keytruda®, E7777, ONTAK®	Alexander B Olawaiye, MD, Dr. Reddys Laboratories, SA	Epithelial Ovarian Cancer	12/25	12/27
NCT05137847: A Study of Remitoro in Participants With Recurrent or Refractory Peripheral T Cell Lymphoma and Cutaneous T Cell Lymphoma (All Case Study)	Completed	N/A	118	Japan	Remitoro, Denileukin diftitox	Eisai Inc.	Lymphoma, T-cell, Peripheral, Lymphoma, T-cell, Cutaneous	03/23	03/23